Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBITDA (2024 - 2025)

Indivior Pharmaceuticals has reported EBITDA over the past 2 years, most recently at $81.0 million for Q4 2025.

  • Quarterly results put EBITDA at $81.0 million for Q4 2025, up 76.09% from a year ago — trailing twelve months through Dec 2025 was $193.0 million (up 348.84% YoY), and the annual figure for FY2025 was $262.0 million, up 589.47%.
  • EBITDA for Q4 2025 was $81.0 million at Indivior Pharmaceuticals, up from $43.0 million in the prior quarter.
  • Over the last five years, EBITDA for INDV hit a ceiling of $81.0 million in Q4 2025 and a floor of -$97.0 million in Q2 2024.